Myelodysplastic syndromes

The VA rates Myelodysplastic syndromes under Diagnostic Code 7725 at 30%, 60%, 100%. The minimum 30% rating requires: Requiring at least 1 but no more than 3 blood or platelet transfusions per 12-month period; infections requiring hospitalization at least 1 but no more than 2 times per 12-month period; or requiring biologic therapy on an ongoing basis or erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period. The maximum 100% rating requires: Requiring peripheral blood or bone marrow stem cell transplant; or requiring chemotherapy.

The VA rates Myelodysplastic syndromes under Diagnostic Code (DC) 7725, governed by 38 CFR 38 CFR § 4.117. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.

A 30% rating requires: Requiring at least 1 but no more than 3 blood or platelet transfusions per 12-month period; infections requiring hospitalization at least 1 but no more than 2 times per 12-month period; or requiring biologic therapy on an ongoing basis or erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period. A 100% rating requires: Requiring peripheral blood or bone marrow stem cell transplant; or requiring chemotherapy. The difference typically reflects the frequency, severity, or functional impact of the condition as documented in medical records and C&P examination findings.

Veterans rated for Myelodysplastic syndromes may qualify for TDIU if the condition — alone or in combination with other service-connected disabilities — prevents substantially gainful employment. A single disability rated at 60% or higher (or multiple disabilities combining to 70%, with one at 40%) can support a TDIU claim under 38 CFR § 4.16.

Service connection for Myelodysplastic syndromes requires three elements: (1) a current diagnosis of the condition, (2) an in-service event, injury, or disease, and (3) a medical nexus linking the current diagnosis to that in-service occurrence. A nexus letter from a treating or independent medical examiner is the most reliable nexus evidence.

A Compensation & Pension (C&P) exam for Myelodysplastic syndromes uses a Disability Benefits Questionnaire (DBQ) specific to the body system involved. The examiner documents the frequency, severity, and functional impact of your symptoms. Bring all relevant treatment records and be prepared to describe your worst-day symptoms — the examiner rates your condition based on the full clinical picture, not a single visit.